Liver iron concentration and distribution in chronic hepatitis C before and after intefferon treatment

Gut

Volumn 41, Issue 1, 1997, Pages 115-120

  Boucher, E ^a,d   Bourienne, A ^a   Adams, P ^c   Turlin, B ^b   Brissot, P ^a   Deugnier, Y ^a  

^a INSERM   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic active C hepatitis; Interferon; Iron overload; Response to interferon treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; IRON; URSODEOXYCHOLIC ACID; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; KUPFFER CELL; LIVER; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030753699     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.41.1.115     Document Type: Article

References (24)

1. Pérez R, Pravia R, Linares A, Rodriguez M, Lombrana JLS, Suarez A, et al. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C. Gut 1993; (suppl): 139S-40S.
2. Payen JL, Izopet J, Selves J, Debzi N, Payen C, Voigt JJ, et al. Predictive factors of relapse after interferon therapy (3 MU TIW for 6 months) in patients treated for chronic HCV infection [abstract]. Hepatology 1994; 20: 158A.
3. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, et al. Iron stores, response to interferon therapy, and effect of ion depletion in chronic hepatitis C. Liver 1996; 16: 248-54.
4. Olynyk J, Reddy R, Di Bisceglie, Jeffers L, Parker T, Radick J, et al. Hepatic iron concentration as a predictor of response to alfa interferon therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-9.
5. Van Thiel D, Friedlander L, Wright H, Irish W, Gavaler J. Response to Interferon is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-5.
6. Di Bisceglie A, Axiotis C, Hoofnagle J, Bacon B. Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2008-13.
7. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis. J Hepatol 1995; 22: 268-71.
8. Hayashi H, Takikawa T, Nishimura N, Yano M. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-8.
9. Guyader D, Boucher E, Even C, Cottereau J, Bianchi A, Gasser P, et al. Iron reduction therapy is inefficient in patients with chronic hepatitis C who failed to respond to Interferon [abstract]. Hepatology 1996; 24: 405A.
10. Barton A, Banner B, Cable E, Bonkovsky H. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995; 103: 419-24.
11. Boucher E, Jouanolle H, André P, Ruffault A, Guyader D, Moirand R, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-6.
12. André P, Clossais-Besnard N. Automated quantitative determination of hepatitis C viremia using reverse transcription-polymerase chain reaction. J Clin Microbiol 1994; 32: 1887-93.
13. Rappaport AM. Hepatic blood flow: morphological aspects and physiological regulation. Int Rev Physiol 1980; 21: 1-63.
14. Deugnier YM, Turlin B, Powell LW, Summers KM, Moirand R, Fletcher L, et al. Differentiation between heterozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases. Hepatology 1993; 17: 30-4.
15. The French METAVIR cooperative study group. Intraobserver and interobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
16. Bedossa P, Poynard T for the METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
17. Barry M, Sherlock S. Measurement of liver-iron concentration in needle-biopsy specimens. Lancet 1971; ii: 100-3.
18. Brissot P, Herry D, Verger JP, Messner M, Regnouard F, Ferrand B, et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 1981; 80: 557-65.
19. Scheuer P. Viral hepatitis. In: MacSween R, Anthony P, Scheuer P, eds. Pathology of the liver. London: Churchill Livingstone, 1988: 201-23.
20. Prieto J, Barry M, Sherlock S. Serum ferritin in patient with iron overload and with acute and chronic liver diseases. Gastoentrology 1975; 68: 525-33.
21. Taetle R, Honeystt M. γ-Interferon modulates human monocyte/macrophage transferrin receptor expression. Blood 1988; 71: 1590-5.
22. Renault P, Hoofnagle J. Side effects of alpha interferon. Scm Liver Dis 1989; 9: 273-7.
23. Loréal O, Chenoufi N, Turlin B, Haziza-Pigeon C, Robert JY, Lescoat G, et al. Effect of ursodeoxycholic acid on liver store and distribution in rat with normal or iron supplemented diet. Liver 1997; 17: 30-4.
24. Shiffman M, Hofman C, Luketic V, Sanyal A, Contos M, Mills S. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996; 24: 21-6.